These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8291869)

  • 1. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single drug polyestradiol phosphate therapy in prostatic cancer.
    Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A
    Am J Clin Oncol; 1988; 11 Suppl 2():S101-3. PubMed ID: 3242384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
    Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
    Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
    J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
    Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E
    Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy.
    Mikkola A; Aro J; Rannikko S; Ruutu M;
    Prostate; 2007 Mar; 67(4):447-55. PubMed ID: 17219379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
    Mikkola AK; Ruutu ML; Aro JL; Rannikko SA; Salo JO
    Br J Urol; 1998 Jul; 82(1):63-8. PubMed ID: 9698663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
    Aro JL; Haapiainen RK; Rannikko SA; Alfthan OS
    Br J Urol; 1989 May; 63(5):512-4. PubMed ID: 2659136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate).
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Aro J; Ervasti J; Hansson E; Hurme K; Juusela H; Mäkinen J
    Ann Chir Gynaecol; 1985; 74(6):277-83. PubMed ID: 4096480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH; Wenderoth UK; Ehrenthal W; von Wallenberg H; Spindler HW; Hohenfellner R
    Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents.
    de Voogt HJ; Adenauer H; Widdra WG
    Scand J Urol Nephrol Suppl; 1991; 138():131-6. PubMed ID: 1838426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
    Banchini A; Zavaroni D; Tarditi E; Cortellini P; Ziveri M; Polotti R; Stefani F; Valenti G
    Minerva Endocrinol; 1989; 14(3):165-8. PubMed ID: 2533662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
    Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
    Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
    Hedlund PO; Henriksson P
    Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.